Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients

Clinical Drug Investigation

Volumn 31, Issue 9, 2011, Pages 605-618

  Elsner, Frank ^a   Zeppetella, Giovambattista ^b   Porta Sales, Josep ^c   Tagarro, Ignacio ^d  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b St Clare Hospice   (United Kingdom)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d Meda Pharmaceuticals   (Spain)

Author keywords

Buccal; Cancer pain; Fentanyl; Intranasal; Opioid analgesics; Pectin; Sublingual

Indexed keywords

ABSTRAL; BREAKYL; FENTANYL; FENTANYL CITRATE; MORPHINE; ONSOLIS; PLACEBO; UNCLASSIFIED DRUG;

CANCER PAIN; CANCER PATIENT; CLINICAL PROTOCOL; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; EMBASE; EUROPE; GOLD STANDARD; HUMAN; MAXIMUM PLASMA CONCENTRATION; MEDLINE; META ANALYSIS; NEUROPATHIC PAIN; NOCICEPTION; PAIN ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TITRIMETRY; UNITED STATES;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; BREAKTHROUGH PAIN; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG TOLERANCE; FENTANYL; HUMANS; MOUTH MUCOSA; NEOPLASMS;

EID: 80051511227     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11592910-000000000-00000     Document Type: Review

References (55)

1. Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009 Apr; 13 (4): 331-8
2. Zeppetella G. Impact andmanagement of breakthrough pain in cancer. Curr Opin Support Palliat Care 2009 Mar; 3 (1): 1-6
3. Fine PG, Busch MA. Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manage 1998 Sep; 16 (3): 179-83 (Pubitemid 28429066)
4. Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002 Feb; 94 (3): 832-9 (Pubitemid 34132314)
5. Breivik H, Cherny N, Collett B, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 2009 Aug; 20 (8): 1420-33
6. Zeppetella G, Ribiero M. Pharmacotherapy of cancer-related episodic pain. Expert Opin Pharmacother 2003; 4 (4): 493-502 (Pubitemid 36511979)
7. Gomez-Batiste X, Madrid F, Moreno F, et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage 2002 Jul; 24 (1): 45-52
8. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice [published erratum appears in J Pain Symptom Manage 2001 Mar; 21 (3): 265]. J Pain Symptom Manage 2000 Aug; 20 (2): 87-92
9. Hagen NA, Stiles C, Nekolaichuk C, et al. The Alberta Breakthrough Pain Assessment Tool for cancer patients: a validation study using a delphi process and patient think-aloud interviews. J Pain SymptomManage 2008 Feb; 35 (2): 136-52
10. Davies A, editor. Cancer-related breakthrough pain. Oxford: Oxford University Press, 2006
11. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990 Jun; 41 (3): 273-81 (Pubitemid 20187930)
12. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999 May; 81 (1-2): 129-34 (Pubitemid 29199908)
13. Ruiz-Garcia V, Lopez-Briz E. Morphine remains gold standard in breakthrough cancer pain [letter]. Br Med J 2008 Dec; 337: a3104
14. Mystakidou K, Tsilika E, Tsiatas M, et al. Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology. Int J Nanomedicine 2007; 2 (1): 49-54 (Pubitemid 46901781)
15. Prommer E. The role of fentanyl in cancer-related pain. J Palliat Med 2009 Oct; 12 (10): 947-54
16. William L, Macleod R. Management of breakthrough painin patients with cancer. Drugs 2008; 68 (7): 913-24 (Pubitemid 351652921)
17. Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001 Mar; 91 (1-2): 123-30 (Pubitemid 32274181)
18. Hanks GW, Nugent M, Higgs CMB, et al. Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study. Palliat Med 2004 Dec; 18 (8): 698-704 (Pubitemid 39654548)
19. ACTIQ®(fentanyl citrate oral transmucosal lozenge): US prescribing information. Frazer (PA): Cephalon Inc. [online]. Available from URL: http://www.actiq.com/pdf/actiq-package-insert-4-5-07.pdf [Accessed 2009 Dec 8]
20. Davies A. Current thinking in cancer breakthrough pain management. Eur J Palliat Care 2005; Suppl.: 4-6
21. Gordon D, Schroeder M. Oral transmucosal fentanyl citrate- OTFC (ACTIQ™) #103. J Palliat Med 2008 May; 11 (4): 633-4 (Pubitemid 351630207)
22. Jacobsen R, Moldrup C, Christrup L. Clinical rationale for administering fentanyl to cancer pain patients: two Delphi surveys of pain management experts in Denmark. J Opioid Manag 2008 Nov-Dec; 4 (6): 383-91
23. Laverty D. Actiq: an effective oral treatment for cancerrelated breakthrough pain. Br J Community Nurs 2007 Jul; 12 (7): 311
24. Laverty D. Treating cancer-related breakthrough pain: the oral transmucosal route. Int J Palliat Nurs 2007 Jul; 13 (7): 326-31
25. FENTORA®(fentanyl buccal tablet): US prescribing information. Frazer (PA): Cephalon Inc. [online]. Available from URL: http://www.fentora.com/pat200- default.aspx[Accessed 2009 Dec 8]
26. European Medicines Agency. Effentora 100 micrograms buccal tablets: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/effentora/effentora.htm [Accessed 2009 Dec 8]
27. Durfee S, Messina J, Khankari R. Fentanyl effervescent buccal tablets. Am J Drug Deliv 2006; 4 (1): 1-5
28. European Medicines Agency. Abstralg 100, 200, 300, 400, 600, 800 microgram sublingual tablets: summary of product characteristics [online]. Available from URL: [Accessed 2009 Dec 8]
29. European Medicines Agency. Instanyl 50 micrograms/dose nasal spray, solution: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/instanyl/emea-combined-h959en.pdf [Accessed 2009 Dec 8]
30. ONSOLIS (fentanyl buccal soluble film): US prescribing information. Somerset (NJ): Meda Pharmaceuticals Ltd [online]. Available from URL: http://www.onsolis.com/pdf/onsolis-pi.pdf [Accessed 2009 Dec 8]
31. Vasisht N, Gever LN, Tagarro I. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open- label, single-dose, crossover study. Clin Drug Investig 2009; 29 (10): 647-54
32. Portenoy RK, Burton AW, Gabrail N, et al., on behalf of the Fentanyl Pectin Nasal Spray 043 Study Group.A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. Pain 2010 Dec; 151 (3): 617-24
33. Taylor D, Galan V, Weinstein SM, et al. Fentanyl pectin nasal spray in breakthrough cancer pain. J Support Oncol 2010 Jul-Aug; 8 (4): 184-90
34. Darwish M, Kirby M, Robertson Jr P, et al. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 mg in healthy adult volunteers. Clin Ther 2006; 28 (5): 707-14 (Pubitemid 44067265)
35. Lennernäs B, Hedner T, Holmberg M, et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 2004; 59 (2): 249-53 (Pubitemid 40208864)
36. Kaasa S, Moksnes K, Nolte T, et al. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid Manag 2010; 6 (1): 17-26
37. Vasisht N, Gever LN, Tagarro I, et al. Single-dose pharmacokinetics of fentanyl buccal soluble film. Pain Med 2010; 11 (7): 1017-23
38. Fisher A, Watling M, Smith A, et al. Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100- 800 mg in healthy volunteers. Int J Clin Pharmacol Ther 2010; 48 (12): 860-7
39. Streisand JB, Busch MA, Talmage DE, et al. Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiol 1998; 88: 305-9 (Pubitemid 28081188)
40. European Medicines Agency. ACTIQ®200, 400, 600, 800, 1200, 1600 microgram compressed lozenge: summary of product characteristics [online]. Available from URL: dicines.org.uk/emc/medicine/11145/SPC/Actiq [Accessed 2009 Dec 8]
41. INSYS Therapeutics. INSYS Therapeutics, Inc. announces positive phase III efficacy trial results for fentanyl sublingual spray [media release]. 2010 Mar 9 [online]. Available from URL: http://www.insysrx.com/news.htm [Accessed 2010Sep 19]
42. Akela Pharma. Akela announces amendment to Fentanyl TAIFUN(R) license agreement with Teikoku Seiyaku [media release]. 2009 Jun 17 [online]. Available from URL:http://www.labinc.ca/modules.php?op=modload&name=News&file= article&sid=90 [Accessed 2010 Sep 21]
43. Kress HG, Oronska A, Kaczmarek Z, et al. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther 2009 Jun; 31 (6): 1177-91
44. Portenoy RK, Taylor D, Messina J, et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006 Nov-Dec; 22 (9): 805-11 (Pubitemid 44627444)
45. Rauck R, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 2009 Dec; 25 (12): 2877-85
46. Slatkin NE, Xie F, Messina J, et al. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007 Jul- Aug; 5 (7): 327-34 (Pubitemid 350055013)
47. Rauck R, North J, Gever L, et al. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol 2010 Jun; 21 (6): 1308-14
48. Mercadante S, Radbruch L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin 2009 Nov; 25 (11): 2805-15
49. European Medicines Agency. European public assessment report (EPAR): Instanyl (fentanyl) [online]. Available from URL: http://www.ema.europa.eu/ema/ index.jsp?curl=pages/medicines/human/medicines/000959/human-med-000838. jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124 [Accessed 2010 Sep 21]
50. European Medicines Agency. European public assessment report (EPAR): Effentora (fentanyl) [online].Available from URL: http://www.ema.europa.eu/ema/ index.jsp?curl=pages/medicines/human/medicines/000833/human-med-000754. jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124 [Accessed 2010 Sep 21]
51. BioDelivery Sciences International Inc. A double-blind placebo controlled evaluation of the efficacy, safety and tolerability of BEMATM fentanyl in the treatment of breakthrough pain in cancer subjects. Clinical study report FEN-201. Raleigh (NC): BioDelivery Sciences International Inc., 2007. (Data on file)
52. Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebocontrolled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998 Apr; 90 (8): 611-6 (Pubitemid 28204805)
53. Farrar JT, Berlin JA, Strom BL. Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manage 2003 May; 25 (5): 406-11 (Pubitemid 36506668)
54. Barden J, Edwards JE, Mason L, et al. Outcomes in acute pain trials: systematic review of what was reported? Pain 2004 Jun; 109: 351-6 (Pubitemid 38638712)
55. Beecher HK. The powerful placebo. J Am Med Assoc 1955 Dec 24; 159 (17): 1602-6